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Abstract
Cancer stem cells (CSCs) or cancer initiating cells (CICs) maintain self-renewal and multilineage 
differentiation properties of various tumors, as well as the cellular heterogeneity consisting of 
several subpopulations within tumors. CSCs display the malignant phenotype, self-renewal ability, 
altered genomic stability, specific epigenetic signature, and most of the time can be phenotyped by 
cell surface markers (e.g., CD133, CD24, and CD44). Numerous studies support the concept that 
non-stem cancer cells (non-CSCs) are sensitive to cancer therapy while CSCs are relatively 
resistant to treatment. In glioblastoma stem cells (GSCs), there is clonal heterogeneity at the 
genetic level with distinct tumorigenic potential, and defined GSC marker expression resulting 
from clonal evolution which is likely to influence disease progression and response to treatment. 
Another level of complexity in glioblastoma multiforme (GBM) tumors is the dynamic 
equilibrium between GSCs and differentiated non-GSCs, and the potential for non-GSCs to revert 
(dedifferentiate) to GSCs due to epigenetic alteration which confers phenotypic plasticity to the 
tumor cell population. Moreover, exposure of the differentiated GBM cells to therapeutic doses of 
temozolomide (TMZ) or ionizing radiation (IR) increases the GSC pool both in vitro and in vivo. 
This review describes various subtypes of GBM, discusses the evolution of CSC models and 
Chongqing Medical University Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND 
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
*Corresponding author. Indiana University Simon Cancer Center, Indiana University School of Medicine, 980 W. Walnut Street, R3-
C524, Indianapolis, IN 46202, USA. Tel.: +1 317 278 4952 (office); fax: +1 317 274 8046. 
Conflicts of interest: No author has a conflict of interest
HHS Public Access
Author manuscript
Genes Dis. Author manuscript; available in PMC 2015 June 29.
Published in final edited form as:
Genes Dis. 2015 June ; 2(2): 152–163. doi:10.1016/j.gendis.2015.02.001.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
epigenetic plasticity, as well as interconversion between GSCs and differentiated non-GSCs, and 
offers strategies to potentially eliminate GSCs.
Keywords
Cancer stem cells; Epigenetic; GBM plasticity; Glioblastoma; Stemness; Dedifferentiation; GBM 
stem cells
Introduction
Glioblastoma multiforme (GBM) comprises the largest group of brain tumors which respond 
very poorly to current therapies.1 In the United States, approximately 13,000 people die 
annually from GBM, and it is disappointing that only about 10% of patients survive 5 
years.2–4 The combination of radiotherapy and adjunct temozolomide (TMZ) has increased 
the survival of patients with GBM, but the median survival of GBM patients is only about 
14.6 months.5 The highly aggressive nature of GBM is due to multiple genetic alterations 
which result in augmented cytoprotective and survival pathways as well as numerous defects 
in the apoptotic signaling machinery and epigenetic alterations (Fig. 1).
A growing body of evidence indicates that rare populations of cancer cells, termed cancer 
stem cells (CSCs) or cancer initiating cells (CICs), play a significant role in several cancers, 
including GBM.6–8 GBM tumors display high degree of phenotypic, cellular, genetic, and 
epigenetic heterogeneity, and it is believed that a major problem in the unresponsiveness of 
GBM tumors to therapy is the existence of GBM stem cells (GSCs) within the tumor which 
are most crucial for driving invasive tumor growth and relapse.6,9 Emerging results have 
revealed that in GBM and other malignancies, CSC enrichment may occur either from an 
increased symmetric self-renewal division rate of CSCs or a reprogramming of non-CSC to 
CSCs and conferring phenotypic plasticity to the tumor population.10 The concept of 
interconversion of CSCs and non-CSCs has provided major complexity in understanding the 
role of CSCs in tumor heterogeneity, a potential mechanism for therapeutic relapse, 
resistance to anticancer therapies, and developing therapeutic strategies. In this review we 
describe various subtypes of GBM, discuss the evolution of CSC models and epigenetic 
plasticity as well as intercon-version between GSCs and differentiated non-GSCs, and offer 
strategies to potentially eliminate GSCs. Understanding GBM tumor cell plasticity and its 
underlying molecular mechanisms will help in the design of more effective therapies against 
GBM and preventing tumor recurrence.
Glioblastoma multiforme (GBM)
GBM comprises the most common and very aggressive form of primary brain tumors which 
respond very poorly to the current therapies.1,2 This most malignant brain tumor is 
designated as World Health Organization (WHO) grade IV astrocytoma which expresses the 
astrocyte marker, glial fibrillary acidic protein (GFAP).11–14 Initiation and recurrence of 
primary GBM may be caused by a subpopulation of GSCs which may derive from mutated 
neural stem and precursor cells.8–14 GBM tumors developed from lower-grade astrocytomas 
or oligodendrogliomas are termed secondary GBMs (Fig. 1). While primary and secondary 
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GBM's are histologically similar, they are genetically different.15,16 Primary GBM 
frequently displays molecular alterations in EGFR, PDGFRA, PTEN, p53 tumor suppressor 
protein, NF1, CDKN2A/B, and telomerase reverse transcriptase (TERT) promoter mutations 
(see Fig. 1).16,17 Furthermore, as reported by Cadieux et al, global hypomethylation is 
frequently observed in primary human GBM.18
Primary GBM is heterogeneous in nature, and based on its patterns of gene expression and 
genetic changes, four different subtypes including proneural, neural, classical and 
mesenchymal have been identified.19,20 While the biological significance and origin of these 
GBM subtypes are unclear, patients with specific GBM subtypes exhibit distinct survival 
times and different responses to therapy.12,19,20 A high frequency of isocitrate 
dehydrogenase 1 (IDH1) mutations and O6-methylguanine-DNA methyl-transferase 
(MGMT) promoter methylation among young adult patients with primary GBM compared 
to other subtypes correlates with increased survival.21 The classical subtype is associated 
with a high frequency of EGFR aberrations and low expression of p53 tumor suppressor 
protein mutations.22 The mesenchymal subtype displays loss of the tumor suppressor gene 
NF1 with high CD44 and MERTK expression, and the neural subtype does not express any 
particular alterations of specific genes or pathways.12,22
The most complete information has been provided by The Cancer Genome Atlas (TCGA) 
Research Network which published a report by analysis of copy number, methylation 
patterns, expression profiling, and whole-genome sequencing of GBM samples.20 Many 
genes including EGFR, PDGFRA, CDK4, MDM2, MDM4, MET, CDK6, N-Myc, Cyclin 
D2, PIK3CA, and AKT3 have been found amplified in GBM, further contributing to the 
complexity in developing therapies to treat GBM.20 Moreover, significant abnormalities in 
several signaling pathways including the receptor tyrosine kinase pathway, the p53 pathway, 
and the RB pathway were found.12,16,20
Cancer stem cell model
GBM tumors display a great degree of phenotypic and functional heterogeneity.7,8,12,13 
Heterogeneity among tumor cells arises within a single tumor as a result of genetic and 
epigenetic changes (Fig. 2) as well as different microenvironments within different regions 
of tumor.23,24 The genetic alterations and epigenetic changes of the cells within the same 
tumor is not well characterized, and for future personalized medicine strategies, it is 
necessary to explore intratumoral heterogeneity with respect to the phenotype and genotype 
of the tumor as well as evaluating its epigenetic alterations to achieve effective treatment for 
GBM.25,26 To better understand intratumoral heterogeneity in a given GBM tumor, 
Sottoriva et al demonstrated that investigating genome-wide GBM intratumoral genomic 
heterogeneity can be used to reveal tumor evolution.25 Furthermore, the authors showed that 
based on gene expression levels, tumor fragments from different anatomical regions of the 
same patient tumor may be classified into different GBM subtypes.25 Significantly, by using 
single-molecule techniques, the authors described the clonal composition of single tumor 
fragments and showed that a hierarchy of mitotic clones coexists within the same fragment 
of tumor. These impressive results unraveled the complexity of GBM tumors with respect to 
their heterogeneity which represents the signature of GBM clonal evolution at the single 
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patient level.25 These results demonstrate the urgent need for personalized medicine and the 
difficulty in developing effective therapies for each GBM patient.
The origin of tumor cell heterogeneity may occur from clonal evolution and from 
differentiation of CSCs.7,27–32 The CSC model well explains the versatility and plasticity of 
heterogeneous tumor populations. This model discusses how very small subpopulations of 
CSCs drive cancer progression and how small subpopulations of cancer cell types with 
specific features are produced within a given tumor.26 CSCs are characterized by their 
ability to generate xenografts representing the initial tumor in immunodeficient animals and 
to divide asymmetrically to allow self-renewal as well as differentiation into a non-CSC 
population (Fig. 3). However, recent experimental evidence showing CSC plasticity 
suggests that the tumor cell populations are dynamic, and both CSCs and non-CSCs are 
capable of interconversion (Figs. 3 and 4) due to environmental factors.7,8,33–39 The 
dedifferentiation of non-CSCs to CSCs further complicates the generation of tumor 
heterogeneity and CSC-targeted therapy.39,40 As stated by Vries et al, any tumor cell can 
revert to a CSC after gaining a clonal advantage over the original CSC during its 
development.28 While much evidence supports the CSC model in several cancers, reliability 
on cell surface markers for identifying authentic CSCs is limited. However, clonal analysis 
and lineage tracing demonstrating the hierarchical organization of tumors in vivo provide 
strong evidence in support of the CSC concept.41,42 In support of this CSC concept, Cheng 
et al by in vivo cell lineage tracing also showed that GSCs contribute to vascular pericytes 
that may remodel perivascular niches.43
The relationship between neuronal stem cells (NSCs) and GSCs as well as differentiation of 
these stem cells are shown in Fig. 2. GSCs like other CSCs are a rare population of slow 
growing cells in tumors which display various “stemness” properties including (1) the 
ability to self-renew and differentiate into distinct lineages through different intermediate 
progenitors, (2) co-existence or heterogeneity of cells with different differentiation 
capacities providing the cellular hierarchy within the tumor, and (3) GSCs have the ability to 
initiate tumors in intra-cranial xenograft models in immunodeficient animals that 
recapitulate phenotypic characteristics of the initial tumor including tumor cell 
heterogeneity, invasiveness, migration and metastasis, tumor hypoxic response; resistance to 
drugs and radiation; resistance of tumors to apoptosis stimuli, and vascular 
characteristics.2,6–8,44,45 Mounting evidence shows that the stem cell niche, i.e., the 
environment in which GSCs reside, is responsible for the maintenance of these cells with 
respect to “stemness” and therapeutic response.36,46–48 The intimate network of various cell 
types and niche paracrine factors are responsible for controlling the necessary signaling 
pathways that regulate the properties of GSCs. As shown in Fig. 3, numerous signaling 
pathways maintain stemness and regulate the tumor propagating capacity of CSCs including 
GSCs.
GSC specific markers
The role of the cell surface protein CD133 (pronin) as a cancer stem cell marker in GBM has 
been extensively investigated. While the CD133 identifies GSCs that form neurospheres and 
generate heterogeneous tumors when transplanted in immune-compromised mice, CD133-
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negative cells displaying similar properties have also been reported.49–54 Interestingly, 
Brescia et al through clonal analysis reported that actually there is not a hierarchical relation 
between CD133-positive and CD133-negative cells, and in fact CD133 is capable of 
changing its subcellular localization between the cytoplasm and the plasma membrane of 
GSC neurospheres.49 Significantly, these authors demonstrated that silencing CD133 in 
human GBM neurospheres using lentivirus-mediated short hairpin RNA impaired the self-
renewal and tumorigenic capacity of neurosphere cells. Interestingly, hypoxia significantly 
increased the percentage of CD133-positive cells from 69% to 92%.55 These data 
collectively suggest that CD133 is indispensible for GSC function and essential for 
maintaining the self-renewal and tumorigenic potential of GBM stem cells.55 Moreover, 
Denysenko et al demonstrated that CD133-positive cell lines showed increased proliferation 
rates in neurospheres and increased differentiation potential towards neuronal lineages, 
while cell lines with low CD133 expression showed mesenchymal properties in vitro.56 
Moreover, other factors may collaborate with CD133 and increase the stemness of GSCs. 
For instance, EGFRvIII contributes to stemness through coexpression with CD133.57 
Moreover, while other biomarkers have been investigated in GBM including L1CAM, 
SOX2, CXCR4, Integrin α–6, and CD36, their roles in GSCs are not well defined.57
While tumor heterogeneity is evident in all four clinically relevant subtypes of GBM as 
described above, molecular signaling in GSCs in individual subtypes is poorly 
characterized.58 In light of this, Mao et al recently identified and characterized two mutually 
exclusive GSC subtypes, proneural (PN) and mesenchymal (Mes) GSCs.58 Mes GSCs 
showed more aggressive phenotypes both in vitro and in intracranial xenografts of GBM in 
mice, and were very resistant to radiation compared with PN GSCs. Interestingly, both the 
glycolytic pathway and ALDH1A3 activities were robustly elevated in Mes but not PN 
GSCs, and inhibition of ALDH1A3 attenuated the growth of Mes but not PN GSCs.
Recent results clearly show the heterogeneity of GSCs that display intrinsically distinct 
tumorigenic ability. By combining ploidy-based flow sorting with array-comparative 
genomic hybridization, Stieber et al found that primary GBMs are either mono- or 
polygenomic tumors (64% versus 36%, respectively) within primary GBMs.26 The authors 
showed that monogenomic tumors are composed of a pseudodiploid tumor clone and normal 
stromal cells, whereas polygenomic tumors consisted of multiple tumor clones and always 
contain a pseudodiploid subpopulation. While multiple tumor GSC clones could generate 
spheroids as well as spheroid-based xenografts, genetically distinct clones had different 
tumorigenic potential. Interestingly, genetically distinct tumor cell populations displayed 
putative GSC markers including CD133, CD15 (SSEA-1), A2B5, and CD44. Therefore, the 
clonal heterogeneity at the genetic level, tumorigenic potential, and GSC marker expression 
may influence GBM progression and govern its response to treatment.26
GBM heterogeneity and GSC plasticity
Recent research efforts have been directed toward selectively targeting CSCs for therapy.29 
However, therapeutic response is influenced by the stemness of a tumor which is defined by 
cancer genetics, epigenetics, microenvironment, and dedifferentiation or conversion of non-
CSCs to CSCs (Fig. 2).7,8,59–63 These processes determine stemness and resistance to drugs 
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and ionizing radiation in GBM tumors. Moreover, growing evidence reveals a high degree 
of plasticity of cancer cells with the ability to effectively and reversibly transit between 
differentiated and CSC pheno-types in response to microenvironmental factors like 
hypoxia.62–67 Therefore, the capacity of tumor cells to mutually interconvert is directed by 
genetic, epigenetic, and microenvironmental regulation by which tumor cells alter their 
phenotypic and functional role which contributes to tumor growth.62–67 A new model 
explaining the differential ability of tumor cells to interconvert explains the concept of “CSC 
plasticity” in which many cells within the tumor can serve as stem cells with various degrees 
of “stemness” regulated by microenvironmental factors.68,69 Indeed, Chaffer et al 
demonstrated that CSC cells can arise de novo from more differentiated cell types and that 
hierarchical models of stem cell biology achieve bidirectional interconversion between stem 
and non-stem compartments (Fig. 2).68
It has been demonstrated that GSCs can be more resistant to conventional anticancer agents 
like TMZ than their differentiated GBM cells.70,71 Conversely, other reports have shown 
that primary GSCs are sensitive to TMZ therapy, and significant expansion of different GSC 
subpopulations after treatment of GBM patients with TMZ has been detected.37,72,73 It has 
been reported that the chemo-resistance of GSCs correlated with elevated levels of the 
detoxifying protein MGMT, which confers strong intrinsic resistance to these cells, and that 
extrinsic factors and conversion of non-CSCs to new CSCs contributes to the resistance of 
CSC to TMZ.74–76 To understand GBM post-therapy, Auffinger et al recently investigated 
the properties of GSCs after primary chemotherapy with TMZ.37 These authors first showed 
that exposure of patient-derived as well as established GBM cell lines to therapeutic doses 
of TMZ increases the GSC pool over time both in vitro and in vivo. Secondly, by performing 
lineage-tracing analysis of the expanded GSC pool, they showed that such increase by TMZ 
was the result of a phenotypic shift in the non-GSC population to a GSC-like state which 
expressed pluripotency and stemness markers such as CD133, SOX2, Oct4, and Nestin. 
Moreover, these new GSCs served as a reservoir for initiating relapse of the tumors.37 The 
phenomenon of spontaneous conversion of a non-CSC population into a CSC-like 
population has also been reported in breast cancer.61 Therefore, collectively, these results 
plus published data on other tumors indicate that the tight cellular hierarchy within a tumor 
(i.e., the initial CSC hypothesis) does not control CSCs, and the cellular heterogeneity of the 
tumor plus cellular plasticity control the stemness of CSCs including GSCs.37,61,77,78
The identification of GSCs has advanced our knowledge of the molecular mechanisms 
involved in regulating GBM development. However, the specific intrinsic factors that 
govern GSCs self-renewal, stemness, differentiation, and dedifferentiation of GBM tumor 
cells to GSCs are not understood.7,8,37,79 Moreover, emerging evidence has revealed that 
specific GBM microenvironments (niches) also play a crucial role in maintaining the 
stemness of GSCs, and that changes in the niches may lead to these processes in 
GSCs.47,80,81 Delineating the molecular mechanisms by which cellular plasticity is 
influenced by niche factors can govern the interconversion of non-CSCs to CSCs and 
enhance the “stemness” of the tumor. This information should provide an important 
direction for developing potentially effective therapies and therapeutic strategies for 
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targeting the heterogeneous GSC subpopulations as well as the bulk of the tumor population 
with the aim of eradicating GBM.
Transcription factors and GCSs
The cellular epigenetic state of an organism (or “epigenome”) incorporates a landscape of 
complex and flexible molecular events that create dynamic plasticity in response to 
environmental cues, and enables cells to function under different conditions with phenotypic 
and functional versatility within cell populations having identical genetic backgrounds.82–84 
This morphological and functional flexibility or plasticity is particularly important for CSCs 
which generate tumor cells that transiently expand and then undergo differentiation to form 
the bulk of the tumor.60,85 However, the underlying molecular mechanisms operating this 
tumor cell plasticity is not clear. Interestingly, using combinatorial mapping of various 
epigenetic markers and gene expression results from GSCs, Suvà et al recently identified a 
core set of four neurodevelopmental transcription factors (TFs) including POU3F2, SOX2, 
SALL2, and OLIG2 essential for GBM propagation.86 Significantly, more than 50% of the 
cells with all four TF (4 TF) also expressed the CSC marker CD133 compared to 4 TF-
negative cells, which lack CD133. These TFs coordinately bind and activate stem-like tumor 
propagating cell (TPC)-specific regulatory elements. Interestingly, they are sufficient and 
essential to totally reprogram differentiated GBM cells and interconvert these cells to 
TPCs.86 These exciting results revealed that these 4TFs are able to reproduce the epigenetic 
characteristic and phenotype of native or initial TPCs. Moreover, by reconstructing the 
transcriptional network controlled by these factors, Suvà et al highlighted critical 
interactions and a regulatory role for a chromatin-modifying complex involving RCOR2 and 
LSD1.86 These significant findings identified the RCOR2/LSD1 histone demethylase 
complex as a candidate therapeutic target in human GBM stem-like TPCs.86 These data 
establish the epigenetic basis of plasticity and evolutionary and developmental hierarchies 
within GBM.86
Another critical transcription factor playing an important role in the GSC phenotype is 
FOXM1, a master regulator of mitotic progression of cancer cells. FOXM1 forms a protein 
complex with the mitotic kinase maternal embryonic leucine zipper kinase (MELK) in 
GSCs, leading to phosphorylation and activation of FOXM1.87 Activated FOXM1 results in 
increased mitotic regulatory genes in GSCs. TMZ treatment enriches both FOXM1- and 
MELK- positive GSCs, and adding Siomycin A, a CSC-targeted agent, to TMZ treatment in 
mice harboring GSC-derived intracranial tumors enhanced the effects of TMZ.87 Identifying 
and developing therapeutic agents to inhibit TFs has been very complex. Since the protein 
complex of FOXM1 with the mitotic kinase MELK in GSCs plays a critical role in GSC 
maintenance, a specific MELK inhibitor, OTSSP167, has been shown to have in vitro and in 
vivo effects on various human cancer xenograft models and is a promising agent for GBM 
therapy.88 Moreover, Minata et al used the multi-kinase inhibitor C1 and showed that it 
induces mitotic catastrophe in GBMs, primarily through MELK kinase inhibition.89
To further understand the regulation of GSC sub-populations, Chudnovsky et al recently 
identified a 397-kDa transcription factor, ZFHX4, which regulates differentiation, and its 
suppression increased GBM-free survival in intracranial xenografts.90 The authors showed 
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that ZFHX4 interacts with CHD4, a core member of the NuRD (nucleosome remodeling and 
deacetylase) complex. Furthermore, using expression data derived from GBM patients, they 
found that ZFHX4 is a regulatory factor that links the chromatin remodeling NuRD complex 
and the GBM tumor initiating cells (TIC) or GSC state.
Epigenetic regulation of GSCs
Known mechanisms of epigenetic gene regulation include (1) chromatin remodeling and 
histone modification, (2) DNA methylation, (3) regulation by polycomb group proteins 
(PcGs), and (4) control and regulation by microRNAs (miR-NAs). Chromatin remodeling 
and histone modification results in histone acetylation and phosphorylation, ubiquitination, 
sumoylation, and ADP-ribosylation. DNA methylation results in covalent modification of 
cytosine nucleotides at the C5 position of particular areas of unmethylated CpG 
dinucleotides.91 PcGs play crucial roles in regulating many cellular processes including 
development, pluripotency, senescence, and cancer.92 PcGs are essential epigenetic factors 
and some members have histone methyltransferase activity.91,93
MicroRNAs and other epigenetic factors in GBCs
miRNAs are non-coding regulatory RNAs that are dysregulated in GSCs, suggesting they 
play an important role in posttranscriptional gene regulation and function in a variety of 
cellular processes.94 Recent results have revealed that miRNAs play important regulatory 
roles in the GSC apoptotic pathway, differentiation, proliferation, migration and invasion, 
drug resistance, and radiation resistance.94,95 Like CSCs from other types of cancer, GSCs 
are controlled by specific receptor signaling and the regulation of stem cell genes by 
transcription factors and miRNAs. Recently, a number of new targets for these regulators for 
GBM treatment have been identified (Fig. 4) and demonstrated that miRNA expression 
patterns are correlated with the developmental lineage and differentiation state of tumor 
cells, as well as innovative biomarkers.94–100 Several published articles have summarized a 
wide range of miRNAs in GSCs and the molecular mechanisms of miRNAs involved in the 
signaling pathways regulating these processes, as well as potential usefulness of miRNAs 
for eliminating GSCs (Fig. 4).96,101–103 From the viewpoint of the CSC hypothesis, several 
deregulated miRNAs have been strongly implicated in regulating the GSCs self-renewal 
capacity, maintenance of stemness and plasticity, and resistance to drugs and radiation 
therapy, as well as unresponsiveness to apoptotic stimuli (Fig. 4).8,103–107 Therefore, 
miRNAs can serve as potential targets for anti-GSC therapeutics.103,108–110
Godlewski et al demonstrated a link between miR-128, which is significantly downregulated 
in GBM, and the loss of GSC self-renewal, which occurs by direct regulation of the neural 
stem cell (NSC) self-renewal factor B lymphoma Mo-MLV insertion region 1 homolog 
(BMI1).110 The polycomb repressor complex (PRC) is an epigenetic regulator of 
transcription and its action is mediated by two protein complexes, PRC1 and PRC2. PRC 
functions as an oncogene in GBM where it is involved in GSC maintenance and 
radioresistance.111 miR-128 directly targets the mRNA of SUZ12, an important component 
of PRC2, in addition to BMI1, a component of PRC1.111 This reduction of SUZ12 
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expression blocks the partially redundant functions of PRC1/PRC2, thereby significantly 
reducing PRC activity and its associated histone modifications.
Epigenetic modifications regulate intratumoral heterogeneity, which is usually regulated by 
specific GSC niches, particularly, perivascular and hypoxic region microenvironments.112 
Moreover, GSC survival, proliferation, and maintenance is regulated by oncogenic 
cytoprotective signaling pathways and epigenetic modifications (Fig. 3).113 Recently, 
Nabilsi et al investigated the extent to which epigenetic differences contribute to 
intratumoral cellular heterogeneity by developing a high-throughput method, termed MAPit-
patch.113 The authors found several differentially expressed and methylated promoters that 
are associated with altered gene expression between NSC and GBM cell populations. In 
addition, considering each promoter individually, substantial epigenetic heterogeneity was 
observed across the sequenced molecules, indicating the presence of epigenetically distinct 
cellular sub-populations within a GBM tumor.113 Their results showed the biological 
relevance of epigenetically distinct sub-populations to the phenotypic heterogeneity of 
tumor cell populations. Moreover, Schonberg et al demonstrated that changes in chromatin 
accessibility without alterations in DNA methylation may comprise a novel class of 
epigenetic biomarkers of GBM.112 A summary of the significance and targets of GSC 
miRNAs is shown in Fig. 4.
While the underlying mechanisms of GSC plasticity are not well established, as discussed 
above, it is regulated by interconversion of GBM tumor cells to GSCs. Mechanistically, 
Natsume et al have shown that this conversion is accompanied by the gain or loss of 
polycomb repressive complex 2 (PRC2), which modifies chromatin structure.114 PRC2 
mediates lysine-27 trimethylation on histone H3 and affects pluripotency or development-
associated genes (e.g., Nanog, Wnt1, and BMP5) in GSCs as well as alterations in the 
subcellular localization of EZH2, a catalytic component of PRC2. Mechanistic studies 
revealed that epigenetic regulation by PRC2 is a key mediator of tumor cell plasticity, which 
is required for the adaptation of GBM cells to their microenvironment.114
Transcriptional mechanisms that control the phenotypic conversion of differentiated tumor 
cells into tumor-propagating stem-like cells remain to be found. Lopez-Bertoni recently 
showed that the reprogramming transcription factors Oct4 and Sox2 trigger GBM cells to 
change into stem-like and tumor-propagating cells via a mechanism involving direct DNA 
methyltransferase (DNMT) promoter transactivation, leading to global DNA methylation 
and DNMT-dependent downregulation of multiple miRNAs.115 They showed that one of the 
miRNAs, miRNA-148a, inhibited GBM cell stem-like properties and tumor-propagating 
potential. These findings identify methylation- and microRNA-based strategies for 
inhibiting the GSCs, their functions, and contributions to tumor growth and recurrence.115
Epigenetic therapy
The identification and development of drugs to correct aberrant epigenetic processes in 
CSCs requires an in depth understanding of the extent and roles of epigenetic 
reprogramming in these cells. Among many alterations, amplification and rearrangements of 
the epidermal growth factor receptor (EGFR) gene are frequently found in GBM. The most 
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common variant is EGFR variant III (EGFRvIII) and this variant could be a marker for 
GSCs showing that epigenetic mechanisms have a role in maintaining heterogeneous 
EGFRvIII expression.116 Demethylation induced a 20% – 60% increase in the percentage of 
EGFRvIII-positive cells, indicating that some cells could re-express EGFRvIII. 
Interestingly, inhibition of histone deacetylation resulted in a 50% – 80% reduction in 
EGFRvIII expression.116
Two main features of cancer are aberrant gene function and altered patterns of gene 
expression, and evidence shows that epigenetic changes in collaboration with genetic 
alterations cause dysregulation in cancer.117,118 However, the epigenetic changes in cancer 
are potentially reversible, and treating CSCs with demethylating agents or HDAC inhibitors 
may potentially reactivate silenced tumor suppressor and TF genes.118 The DNA 
methyltransferase (DNMT) 5-azacytidine is an effective anticancer agent and inhibitor of 
GSCs.119–121 Another class of epigenetic inhibitors are HDAC inhibitors. HDACs are a 
family of 18 deacetylating enzymes that remove acetyl groups from lysine residues of 
histone proteins and other proteins including TFs.122 HDACs regulate the conformation and 
activity of chromatin and mostly function as transcriptional co-repressors as part of large 
multi-protein complexes.122 HDAC inhibitors and DNA damaging agents synergistically 
inhibit the growth and induce apoptosis in GSC cells possibly because they promote an open 
chromatin conformation and allow more effective access of DNA damaging agents to the 
chromatin, resulting in the increased effectiveness of these agents.12
Clinical significance of GSC plasticity
For the future of personalized medicine for cancer patients, delineating the molecular 
mechanisms to predict the therapeutic response in GBM is critically important. A major 
challenge is to identify molecular predictors of response to new drugs. However, in the 
absence of such detailed molecular mechanisms, it is still possible to some degree to predict 
the response of GBM tumors to therapy. For example, in GBM cells TMZ is cytotoxic to 
cells by triggering DNA damage, but it can be rapidly repaired by the protein MGMT. In a 
subset of GBM, the MGMT promoter methylation, impairs the repair mechanism and 
confers chemosensitivity.123 While numerous GSC targeted therapies have been identified, 
the usefulness of these compounds from the viewpoint of pharmacokinetics and toxicity 
profiles and whether they cross the blood–brain barrier (BBB) remain to be found. 
Repurposing FDA-approved drugs which are clinically used for other diseases may identify 
effective agents for GBM therapy. For example, several drugs that target epigenetic 
alterations, including HDAC inhibitors and DNA methyltransferase (DNMT), approved for 
hematological malignancies, are available for solid tumor therapy.124 Recently, Jiang et al 
used GBM cells and GSCs to identify several FDA-approved compounds that potentially 
could be useful in GBM treatment.125 Their findings provided the basis for the rational 
combination of statins and topoisomerase inhibitors for GBM therapy. Moreover, using 
high-throughput chemical screens, Hothi et al identified an FDA-approved agent for the 
treatment of alcoholism, disulfiram (DSF), as an inhibitor of human GSCs.126 Interestingly, 
DSF is a relatively non-toxic drug that can cross the BBB, and it is a direct and potent 
inhibitor of human MGMT in brain tumor cells.126,127 These results support the repurposing 
of DSF for GBM therapy.127 Another group of agents potentially useful for GBM therapy 
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are epigenetic inhibitors. For example, treating GSCs with the histone deacetylase inhibitors 
Trichostatin A (TSA) and valproic acid (VPA) significantly reduced proliferation rates, 
decreased the expression of stem cell markers, and induced differentiation of these cells.128 
Using these agents may increase the efficacy of conventional cancer treatments for 
eliminating GSCs. Moreover, it has been shown that GBM patients have displayed stable 
disease and partial responses to the redox agent perylene-quinone hypericin (HYP), a 
compound targeting multiple epigenetic mechanisms.129
Future directions
While considerable progress has been made toward isolating GSCs, it is still not clear what 
the molecular characteristics of authentic GSCs are. Therefore, identifying the specific and 
reliable biomarkers of GSCs is critical. Current studies have shown the presence of distinct 
sub-populations of GSCs within a single GBM tumor. Therefore, it would be critically 
important to develop therapeutic strategies that contain agents targeting different signaling 
pathways and/or employing effective multi-targeting agents to eradicate these GSCs which 
display several phenotypic, genotypic and epigenetic characteristics. Mounting evidence 
supports a model of tumorigenicity with considerable plasticity between the non-GSC and 
GSC subpopulations within a GBM tumor, and particularly interconversion of the 
differentiated non-GSCs to GSCs upon chemotherapy treatment. Investigating specific niche 
factors which influence the interconversion between GSCs and non-GSCs will provide 
significant information on the role of microenvironment on GSC plasticity. Moreover, 
understanding the molecular mechanisms of how cellular plasticity can govern the 
interconversion of non-CSCs to CSCs and enhance the “stemness” of the tumor is required 
for developing effective therapeutic strategies to treat GBM. Targeting the mechanisms 
associated with drug-and ionizing radiations (IR)-induced dedifferentiation and plasticity 
may potentially lead to the development of rational therapeutic strategies for treatment of 
GBM.
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Figure 1. Genetic alterations and aberrant signaling pathways in primary and secondary GBM
A. The continued growth and recurrence of primary GBM is due to the presence of GSCs 
which express various protein markers and display self-renewal and tumorigenic potential. 
Modified from Masui et al.15 B. Epigenetic changes in GBM. Numerous molecular 
alterations shown in this figure and described in the text occur in primary GBM. Mutations 
in p53 tumor suppressor protein (p53) and ATRX typically occur in low-grade gliomas and 
secondary GBM. Mutation of the IDH1 gene is commonly found in low-grade gliomas and 
secondary GBM, but is rare in primary GBM. Mutation of IDH1 leads to aberrant DNA 
methylation and mutations in the important chromatin modifier ATRX, affecting chromatin 
structure. Figure was modified from Kondo et al.16
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Figure 2. Relationship between neuronal stem cells, differentiation, GSCs, cancer initiation, and 
dedifferentiation
NSCs are able to differentiate into neural progenitors. Neural progenitors differentiate into 
neurons and glial progenitors differentiate to oligodendrocytes, ependymal cells, and 
astrocytes. GBM is initiated from the transformation of NSCs into GSCs. Similarly, glial 
progenitors are able to trigger tumor development following malignant transformation of 
normal progenitor cells. Astrocytes, neurons, oligodendrocytes, and ependymal cells also 
have the potential to initiate tumorigenesis.33
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Figure 3. Multiple signaling networks in GSCs
A complex and integrated signaling network governs self-renewal, stemness, and maintaince 
of CSCs including GSCs. As shown in this figure, this network of proteins belong to many 
pivotal cellular pathways and include several plasma membrane receptors, cytoplasmic 
signaling proteins, specific transcription factors, growth factors, and ligands.
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Figure 4. MicroRNAs identified in GSCs
A summary of deregulated microRNAs regulating various cellular processes is listed. This is 
summary of the previously reported publications cited in the reference list.16,64,96,97,130
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